drugset / Trial / NCT07248839

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

NCT07248839

Phase 1 Recruiting 24 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the pharmacokinetic and safety of BMS-986435 in participants with normal hepatic function and participants with different degrees of hepatic impairment

Timeline

Start
2025-12-15
Primary completion
2026-08-05
Completion
2026-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject DELOCAMTEN Small molecule

Indications

No indication recorded.